CYP2C19 and Stroke: The pooled results showed that carriers of CYP2C19 LOF alleles are at significant higher risk of stroke after receiving clopidogrel-based antiplatelet therapy, compared to non-carriers (RR: 1.68, 95%CI: 1.04–2.71, P = 0.03), and this association was scored as “moderate quality” using the GRADEpro tool.